Acorda completes Neuronex acquisition as diazepam nasal spray nears NDA
This article was originally published in Scrip
Acorda Therapeutics paid $6.8 million on 20 December to complete the acquisition of Neuronex and the Ardsley, New York-based company will make up to $134 million in additional milestone payments plus royalties for Neuronex's patient-friendly intranasal formulation of diazepam for the control of acute repetitive seizures (ARS).
You may also be interested in...
Even Series A rounds have been large during recent record-breaking years for biotech venture capital investment, but it looks like smaller financings for early-stage companies may be in the midst of a comeback. With VC firms closing new funds, that raises the question: Will the number of preclinical and Phase I financings increase?
Private Company Edition: TVM, Focus/MD Anderson and RA Capital launched new venture capital funds. Also, LianBio’s $310m crossover financing, AavantiBio’s Sarepta-backed $107m series A and Sirnaomics’ $105m series D led recent VC rounds.
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.